1. Home
  2. CRSP vs CRK Comparison

CRSP vs CRK Comparison

Compare CRSP & CRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • CRK
  • Stock Information
  • Founded
  • CRSP 2013
  • CRK 1983
  • Country
  • CRSP Switzerland
  • CRK United States
  • Employees
  • CRSP N/A
  • CRK N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • CRK Oil & Gas Production
  • Sector
  • CRSP Health Care
  • CRK Energy
  • Exchange
  • CRSP Nasdaq
  • CRK Nasdaq
  • Market Cap
  • CRSP 4.9B
  • CRK 4.7B
  • IPO Year
  • CRSP 2016
  • CRK N/A
  • Fundamental
  • Price
  • CRSP $59.62
  • CRK $17.39
  • Analyst Decision
  • CRSP Buy
  • CRK Hold
  • Analyst Count
  • CRSP 16
  • CRK 10
  • Target Price
  • CRSP $72.27
  • CRK $19.50
  • AVG Volume (30 Days)
  • CRSP 1.8M
  • CRK 2.0M
  • Earning Date
  • CRSP 11-04-2025
  • CRK 10-29-2025
  • Dividend Yield
  • CRSP N/A
  • CRK N/A
  • EPS Growth
  • CRSP N/A
  • CRK N/A
  • EPS
  • CRSP N/A
  • CRK N/A
  • Revenue
  • CRSP $38,050,000.00
  • CRK $1,654,969,000.00
  • Revenue This Year
  • CRSP N/A
  • CRK $55.29
  • Revenue Next Year
  • CRSP $348.18
  • CRK $16.22
  • P/E Ratio
  • CRSP N/A
  • CRK N/A
  • Revenue Growth
  • CRSP N/A
  • CRK 20.80
  • 52 Week Low
  • CRSP $30.04
  • CRK $9.73
  • 52 Week High
  • CRSP $71.13
  • CRK $31.17
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 60.26
  • CRK 58.59
  • Support Level
  • CRSP $51.63
  • CRK $15.52
  • Resistance Level
  • CRSP $62.08
  • CRK $16.54
  • Average True Range (ATR)
  • CRSP 2.52
  • CRK 0.66
  • MACD
  • CRSP 0.84
  • CRK 0.35
  • Stochastic Oscillator
  • CRSP 78.13
  • CRK 88.69

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About CRK Comstock Resources Inc.

Comstock Resources Inc is an independent natural gas producer operating in the Haynesville shale, a natural gas basin located in North Louisiana and East Texas with superior economics given its geographical proximity to the Gulf Coast natural gas markets. The Company operates in one business segment, the exploration and production of North American natural gas and oil. It is engaged in the acquisition, development, production, and exploration of oil and natural gas. Its oil and gas operations are concentrated in Louisiana and Texas.

Share on Social Networks: